CNS distribution and preclinical activity of the PI3K/AKT inhibitors inavolisib and ipatasertib in pediatric-type diffuse high-grade gliomas

Leire Balaguer-Lluna, Clàudia Resa-Parés, Lucas Brstilo, Alberto Gómez-Caballero, Mercè Baulenas-Farrés, Jacqueline Mohr, Yutian Hu, Rosario Aschero, Ana Rodríguez, Gaia Botteri, Eva Rodríguez, Lydia Li-Chen, Raúl Mañogil, Federica Marino, Nuria Martínez-Velasco, Alex Ruano, Ángela García-Pelayo, Au · 2026

Read CNS distribution and preclinical activity of the PI3K/AKT inhibitors inavolisib and ipatasertib in pediatric-type diffuse high-grade gliomas by Leire Balaguer-Lluna, Clàudia Resa-Parés, Lucas Brstilo, Alberto Gómez-Caballero, Mercè Baulenas-Farrés, Jacqueline Mohr, Yutian Hu, Rosario Aschero, Ana Rodríguez, Gaia Botteri, Eva Rodríguez, Lydia Li-Chen, Raúl Mañogil, Federica Marino, Nuria Martínez-Velasco, Alex Ruano, Ángela García-Pelayo, Au (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13585860.txt.

Introduction

Brain tumors in children that spread through the midline are among the hardest cancers to treat, and many run on a growth pathway called PI3K/AKT. Leire Balaguer-Lluna and co-authors tested two drugs that block that pathway in a 2026 preclinical study. The key question was whether the drugs even reach the brain in useful amounts.

The team screened 12 tumor cell lines, all carrying pathway faults, for sensitivity to the two inhibitors, inavolisib and ipatasertib. One line with a common mutation stood out as the most sensitive. In mice, they modeled how much of each oral dose reached brain tissue and spinal fluid. They then treated mice bearing that sensitive tumor inside the skull, tracking survival and tumor DNA in spinal fluid. The work maps the drugs' reach before any child is exposed.

Catalog record

CREATORLeire Balaguer-Lluna, Clàudia Resa-Parés, Lucas Brstilo, Alberto Gómez-Caballero, Mercè Baulenas-Farrés, Jacqueline Mohr, Yutian Hu, Rosario Aschero, Ana Rodríguez, Gaia Botteri, Eva Rodríguez, Lydia Li-Chen, Raúl Mañogil, Federica Marino, Nuria Martínez-Velasco, Alex Ruano, Ángela García-Pelayo, Au
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE48 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13585860

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

CNS distribution and preclinical activity of the PI3K/AKT inhibitors inavolisib and ipatasertib in pediatric-type diffuse high-grade gliomas Authors: Leire Balaguer-Lluna, Clàudia Resa-Parés, Lucas Brstilo, Alberto Gómez-Caballero, Mercè Baulenas-Farrés, Jacqueline Mohr, Yutian Hu, Rosario Aschero, Ana Rodríguez, Gaia Botteri, Eva Rodríguez, Lydia Li-Chen, Raúl Mañogil, Federica Marino, Nuria Martínez-Velasco, Alex Ruano, Ángela García-Pelayo, Auriane Giron, Jaume Mora, Cinzia Lavarino, Macarena Sánchez-Navarro, Meritxell Teixidó, Aida Ormazabal, Rafael Artuch, Nora Unceta, Paula Schaiquevich, Angel M Carcaboso Published: 2026 ABSTRACT AbstractPurposePediatric-type diffuse high-grade gliomas (pHGG) are aggressive, largely incurable malignancies often characterized by PI3K/AKT pathway activation. This study investigated whether the PI3K inhibitor inavolisib and the AKT inhibitor ipatasertib could achieve therapeutic concentrations in the central nervous system (CNS) and demonstrate efficacy against PIK3CA-mutated pHGG.MethodsA panel of 12 pHGG cell lines with diverse PI3K/AKT genetic aberrations was screened for sensitivity to inavolisib and ipatasertib. Pharmacokinetic (PK) modeling was performed in mice to determine brain-to-plasma exposure ratios following oral administration (50 mg/kg inavolisib and 100 mg/kg ipatasertib). Finally, the in vivo efficacy of both inhibitors was evaluated using intracranial PIK3CA-mutated pHGG xenograft models, with survival and cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) levels as primary endpoints.ResultsAll 12 cell lines exhibited PI3K/AKT alterations. The PIK3CA H1047R-mutated line (HSJD-DIPG-007) was the most sensitive in vitro (IC50 = 0.016 µM for inavolisib; 0.52 µM for ipatasertib). PK modeling revealed geometric mean brain-to-plasma ratios of 0.07 for inavolisib and 0.20 for ipatasertib, with model-predicted maximum brain concentrations of 0.69 µM and 0.93 µM, respectively. In vivo, inavolisib significantly extended survival (P = 0.0070) and increased CSF ctDNA release (P = 0.0317). In contrast, ipatasertib did not demonstrate significant in vivo activity.ConclusionThese findings highlight the therapeutic potential of inavolisib for treating PIK3CA-mutated pHGG. Despite the blood-brain barrier, inavolisib achieved sufficient CNS exposure to prolong survival in preclinical models, whereas ipatasertib efficacy did not translate from in vitro to in vivo settings.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s00280-026-04950-5.Keywords: Pediatric-type diffuse high-grade glioma (pHGG), Diffuse midline glioma (DMG), PI3K/AKT inhibitors, Inavolisib (GDC0077), CNS pharmacokinetics, PIK3CA-mutant xenografts Introduction Pediatric-type diffuse high-grade gliomas (pHGG) represent a group of highly aggressive malignancies of the central nervous system (CNS) [1]. Within the current WHO classification of CNS tumors, the diffuse midline glioma (DMG), H3 K27-altered, is the most prevalent molecular subclass, accounting for 80% of cases [2]. These tumors are primarily driven by somatic mutations in genes encoding histone H3.3 (H3F3A) or H3.1 (HIST1H3B, HIST1H3C), typically resulting in a lysine-to-methionine substitution at position 27 (K27M) [3, 4]. The most frequent clinical manifestation of DMG is diffuse intrinsic pontine glioma (DIPG), which originates in the brainstem. Most pHGG remain incurable and, for patients with DMG, surgical resection is clinically unfeasible due to the profuse infiltration of the tumor into vital neuroanatomical structures. Since the discovery of oncogenic H3 K27 alterations in 2012, direct targeting of these mutations has remained clinically elusive, prompting research into alternative molecular vulnerabilities [5]. A primary candidate is the signaling axis involving receptor tyrosine kinases (RTK), phosphatidylinositol 3-kinase (PI3K), and protein kinase B (AKT). This pathway is constitutively activated by genomic alterations in 60% of pHGG [6]. For instance, approximately 10% of DMG cases harbor mutations in PIK3CA, the gene encoding the class I PI3K α isoform (p110α) [7]. While all three components of the RTK/PI3K/AKT pathway are targetable with small-molecule inhibitors developed over the last two decades [8–10], early clinical trials utilizing RTK inhibitors such as imatinib, vandetanib, and dasatinib failed to demonstrate significant activity in patients with pHGG. This lack of efficacy has been partially attributed to poor CNS drug penetration and distribution [11, 12]. The penetration of small molecules into the brain is commonly estimated using the brain-to-plasma area under the concentration-time curve (AUC) ratio. This assessment can be further refined by considering the protein-unbound fractions (representing the free molecules capable of traversing into brain tissue) and the ratio of unbound concentrations in the brain and plasma at steady state [13]. In most diffuse pediatric gliomas, the blood-brain barrier (BBB) remains largely intact [14]. This integrity contributes to the relatively low brain-to-plasma ratios observed in murine models for earlier inhibitors, such as 0.03 (i.e., 3%) for imatinib [15], 0.2 for vandetanib [16], and 0.1 for dasatinib [17]. More recently, the dual PI3K/mTOR inhibitor paxalisib demonstrated superior CNS penetration, with brain-to-plasma ratios exceeding 1 in rats and mice [18]. Paxalisib has since transitioned to clinical evaluation in patients with adult gliomas [19] and pHGG [20], where it has shown signs of activity in specific cohorts and achieved clinically relevant concentrations of approximately 1 µM in both brain and tumor tissue [19, 20]. This molecule continues in clinical evaluation in pHGG, while others, such as the AKT inhibitors, remain relatively unexplored. In this study, we evaluated the pharmacology and CNS pharmacokinetics (PK) of two targeted inhibitors of the PI3K/AKT pathway. The first, inavolisib (GDC-0077), is a selective inhibitor of the PI3K p110α subunit and is an FDA-approved treatment for patients with metastatic PIK3CA-mutated breast cancer, following its landmark approval for use in combination therapies [21, 22]. Ipatasertib (GDC-0068), a selective ATP competitive pan-AKT inhibitor [23], underwent extensive evaluation in phase 3 clinical trials for metastatic prostate cancer [24]. However, its development was clinically discontinued after results fell below expected activity and safety thresholds. To date, neither inavolisib nor ipatasertib have been sufficiently tested in preclinical pHGG models and remain unassessed in clinical trials involving children with pediatric cancer. Crucially, their distribution within the CNS and diffuse high-grade gliomas is not entirely understood [25, 26]. The initial purpose of this work was to systematically assess the presence of RTK/PI3K/AKT alterations across a panel of 12 established pHGG cell lines. We then investigated the CNS disposition and anticancer efficacy of both inavolisib and ipatasertib in vivo, utilizing intracranial pHGG xenograft models with PIK3CA mutations, which we expected to be sensitive to inavolisib. Materials and methods Cell models Primary cancer cell models, all pHGG (Supplementary Table S1), were established in our previous work at Hospital Sant Joan de Deu (HSJD, Barcelona, Spain) and cultured as tumorspheres in serum-free, B27-supplemented medium (pHGG medium) [27]. We obtained the human cerebral microvascular endothelial cells hCMEC/D3 from Sigma-Aldrich (Saint Louis, MO, USA) and cultured them in endothelial cell growth medium (Promocell, Heidelberg, Germany). Intracranial xenografts We performed animal experimentation according to the Institutional and European guidelines (EU Directive 2010/63/EU) and with the approval of the local animal care and use committee from the University of Barcelona, Spain (protocol 135/11). We used 4-week-old athymic nude mice, all female (Inotiv, Barcelona, Spain). For xenografting, we inoculated 5 × 105 HSJD-DIPG-007 (abbreviated DIPG-007) or HSJD-GBM-001 (GBM-001) cells [27], dispersed in 5 µL matrigel (BD Biosciences, San Diego, CA, USA), in the fourth ventricle of the brain. For this procedure, mice were anesthetized and immobilized in a stereotaxic apparatus (Stoelting, Wood Dale, IL), as previously described [27]. Inhibitors Ipatasertib (GDC-0068) and inavolisib (GDC-0077) were generously provided by Hoffmann-La Roche Ltd. (Basel, Switzerland). For in vitro assays, we prepared stock solutions in dimethyl sulfoxide (DMSO, Sigma-Aldrich) and stored them at -20 °C until use. Whole exome sequencing (WES) Details for the extraction of DNA of cell lines, genomic DNA library and analysis are published [27]. Immunofluorescence For the detection of

Read the complete text